Anavex Life Sciences Corp.

232 articles with Anavex Life Sciences Corp.

• Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia

  10/15/2020

  Clinically meaningful, dose-dependent, and statistically significant improvements in theCognitive Drug Research(CDR) computerized assessmentsystem analysis

• Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial

  9/10/2020

  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the completion of the ANAVEX ® 2-73 ( blarcamesine ) U.S. Phase 2 study in Rett syndrome. The Com

• Anavex Life Sciences to Present at Upcoming Global Healthcare ConferencesCantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Global Investment Conference

  9/8/2020

  Anavex Life Sciences Corp. announced that its President & Chief Executive Officer, Christopher U. Missling, PhD, will present a company update at both the Cantor Fitzgerald Global Healthcare Conference 2020 and the H.C. Wainwright 22nd Annual Global Investment Conference.

• Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Parkinson’s Disease

  8/19/2020

  Anavex Life Sciences Corp. announced that the Shake It Up Foundation for Parkinson’s Research and its international partners has committed to invest into Anavex up to 50% of the costs of a disease modifying clinical study to develop ANAVEX®2-73 for the disease modifying treatment of Parkinson’s disease.

• Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business UpdatesConference Call and Webcast Today at 11:00 a.m. ET

  8/6/2020

  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal 2020 third quarter. “It is an accomplishment having three ongoing

• Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease Patients

  8/5/2020

  Compassionate Use Special Access Scheme Approval for Alzheimer’s Patients to Continue Treatment with ANAVEX®2-73 (blarcamesine) after Completing the 5-Year ANAVEX®2-73-003 Phase 2a Clinical Study

• Anavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results on Thursday, August 6th, 2020Conference Call and Webcast To be Held Thursday, August 6, 2020 11:00 am Eastern Time

  8/4/2020

  Anavex Life Sciences Corp. announced that it will issue financial results for its fiscal quarter ended June 30, 2020 on Thursday, August 6th, 2020.

• Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)

  7/6/2020

  Anavex Life Sciences Corp. announced the enrollment of the first participant in a Phase 1 clinical trial of ANAVEX®3-71, an orally-administered small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases with topline data anticipated in the first half of 2021.

• Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett Syndrome

  7/1/2020

  Anavex Life Sciences Corp. announced that the first patient was dosed in the EXCELLENCE Phase 2/3 ANAVEX®2-73-RS-003 clinical trial for the treatment of Rett syndrome with ANAVEX®2-73.

• Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial

  6/16/2020

  Anavex Life Sciences Corp. announced that it has surpassed by 50% the company’s original enrollment target for the ANAVEX®2-73 U.S. Phase 2 study in Rett syndrome.

• Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s Disease

  6/4/2020

  The 48-week Phase 2b/3 study ANAVEX®2-73-AD-004 of ANAVEX®2-73 using biomarker and precision medicine in 450 patients with early Alzheimer’s disease is ongoing and currently over 50% enrolled.

• Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)

  5/21/2020

  Anavex Life Sciences Corp. announced the approval by the Australian Human Research Ethics Committee to initiate the First-in-Human clinical study of ANAVEX®3-71, an orally-administered small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases.

• Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business Updates

  5/7/2020

  Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system diseases, reported financial results for its fiscal 2020 second quarter.

• Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020Conference Call and Webcast To be Held Thursday, May 7 2020 4:30pm Eastern Time

  5/5/2020

  Anavex Life Sciences Corp. announced that it will issue financial results for its fiscal quarter ended March 31, 2020 on Thursday, May 7th, 2020.

• 

  Clinical Catch-Up: April 20-24

  4/27/2020

  Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.

• Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s Disease

  4/23/2020

  Published in Alzheimer's & Dementia Journal, Results Highlight ANAVEX®2-73 (blarcamesine) Clinical Study, the First Reported Genome-Wide Search for Biomarkers Associated with Drug Response in Alzheimer’s Disease

• Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19

  3/31/2020

  Anavex Life Sciences Corp. provided an update on the evolving COVID-19 condition and the Company’s response to its clinical program development.

• Anavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders

  3/23/2020

  Anavex Life Sciences Corp. will hold its Annual Meeting of Shareholders (Annual Meeting) on Tuesday, April 7, 2020 at 10:00 a.m. ET.

• Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS)

  2/24/2020

  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the publication in the peer-reviewed Journal of Neuroimmunology,

• Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study UpdatesConference Call and Webcast Today at 4:30 p.m. ET

  2/6/2020

  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal 2020 first quarter.